A study on the metabolism of etoposide and possible interactions with antitumor or supporting Agents by Human Liver Microsomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 3, 1998, Pages 1294-1300

  Kawashiro, Takashi ^a   Yamashita, Kouwa ^a   Zhao, Xue Jun ^a   Koyama, Eriko ^a   Tani, Masayoshi ^a   Chiba, A N ^a   Ishizaki, Takashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; ETOPOSIDE; KETOCONAZOLE; PREDNISOLONE; QUININE; TESTOSTERONE; TROLEANDOMYCIN; VERAPAMIL; VINCRISTINE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; ISOENZYME; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CATALYSIS; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; DEMETHYLATION; DRUG METABOLISM; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MULTIDRUG RESISTANCE; PODOPHYLLUM; PRIORITY JOURNAL; DEALKYLATION; DRUG INTERACTION; FEMALE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; HUMANS; ISOENZYMES; MALE; MICROSOMES, LIVER; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0032159284     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T and Ishizaki T (1993a) Oxidative metabolism of omeprazole in human liver microsomes: desegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59.
2. MP) activity in human liver samples obtained as surgical waste from Japanese patients. Drug Metab Dispos 21:747-749.
3. Chiba K, Manabe K, Kobayashi K, Takayama Y, Tani M and Ishizaki T (1993c) Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes. Eur J Clin Pharmacol 44:559562.
4. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M and Ishizaki T (1994) The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 37:237-242.
5. Clark PI and Slevin ML (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223-252.
6. Fisher RI, DeVita VT Jr, Hubbard SM, Longo DL, Wesley R, Chabner BA and Young RC (1983) Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304-309.
7. Goldstein JA and de Morals SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
8. Hande KR, Wolff SN, Greco A, Hainsworth JD, Reed G and Johnson DH (1990) Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 8:11011107.
9. Henderson RG, Wheatley T, English J, Chakraborty J and Marks V (1979) Variation in plasma prednisolone concentration in renal transplant recipients given entericcoated prednisolone. Br Med J 1:1534-1537.
10. Kandrotas RJ, Slaughter RL, Brass C and Jusko WJ (1987) Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous Cortisol. Clin Pharmacol Ther 42:465-470.
11. Koyama E, Sohn DR, Shin SG, Chiba K, Shin JG, Kirn YH, Echizen H and Ishizaki T (1994) Metabolic disposition of imipramine in Oriental subjects: Relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J Pharmacol Exp Ther 271:860-867.
12. Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf CR and Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg Arch Pharmacol 348:332-337.
13. Kronbach T, Fischer V and Meyer UA (1988) Cyclosporin metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporinmetabolizing enzyme explains interactions of cyclosporin with other drugs. Clin Pharmacol Ther 43:630-635.
14. Lowry OH, Rosebrough NJ, Fair AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
15. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J and Sikic BI (1993) Clinical trials of modulation of multidrug resistance: Pharmacokinetic and pharmacodynamic considerations. Cancer 72(SuppI.):3502-3514.
16. Lum BL and Gosland MP (1995) MDR expression in normal tissues: Pharmacologie implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319-336.
17. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsen J, Gosland MP and Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642.
18. Murray N (1997) Treatment of small cell lung cancer: The state of the art. Lung Cancer 17:S75-S89.
19. Nelson RL, Dyke RW and Root MA (1980) Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 7(Suppl.):17-24.
20. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 3:566-573.
21. Relling MV, Evans R, Dass C, Desiderio DM and Memec J (1992) Human cytochrome P450 metabolism of teniposide and etoposide. JPharmacol Exp Ther 261:491-406.
22. Relling MV, Evans WE, Fonné-Pfister R and Meyer UA (1989) Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and meplienytoin hydroxylase, in human liver microsomes. Cancer Res 49:68-71.
23. Relling MV, Memec J, Schuetz EG, Schuetz JD, Gonzalez FJ and Korzekwa ICR (1993) 0-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352-358.
24. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
25. Stahelin HF and von Wartburg A (1991) The chemical and biological route frcm podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture. Cancer Res 51:5-15.
26. Stewart CF (1994) Use of etoposide in patients with organ dysfunction: Pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 34(Suppl.):S76-S8S.
27. Stewart CF, Arburk SG, Fleming RA and Evans WE (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8:1874-1879.
28. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gerboin HV and Miners JO (1993) Specificity of substrate and inhibitor probss for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
29. Thorgeirsson SS, Silverman JA, Gant TW and Marino PA (1991) Multidrug resistance gene family and chemical carcinogens. Pharmacol Ther 49:283-292.
30. Thummel KE, Kharasch ED, Podoll T and Kunze K (1993) Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 21:350-357.
31. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA and Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 :n human liver. Proc Natl Acad Sei USA 82:6310-6314.
32. Waxman DJ, Attisano C, Guengerich FP and Lapenson DP (1988) Human liver microsomal steroid metabolism: Identification of the major microsomal stero\d hormone 6/3-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263: 424-436.
33. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
34. Yasumori T, Murayama N, Yamazoe Y and Kato R (1990) Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-4EO human-2. Clin Pharmacol Ther 47:313-322.
35. Yoshimoto K, Echizen H, Chiba K, Tani M and Ishizaki T (1995) Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 39:421431.
36. Yun CH, Shimada T and Guengerich FP (1991) Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 40:679-685.
37. Zhao X-J and Ishizaki T (1997) Metabolic interaction of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol 44:505-511.
38. Zhao X-J, Kawashiro T and Ishizaki T (1998) A mutual inhibition between quinine and etoposide by human liver microsomes. Drug Metab Dispos 26:188-191.
39. Zhao X-J, Yokoyama H, Chiba K, Wanwimolruk S and Ishizaki T (1996) Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of qu nine by human liver microsomes and nine recombinant human cytochrome P450. J Pharmacol Exp Ther 279:1327-1334.
40. Zhou-Pan XR, Séréé E, Zhou XJ, Placidi M, Maurel P, Barra Y and Rahmani R ( 199E ) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interaction. Cancer Res 53:5121-5126.
41. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P and Rahmani R (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation: Metabolic drug interaction. Biochem Pharmacol 45:853-861.